These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9794155)

  • 1. A study comparing biopharmaceutic characteristics of four once daily controlled release diltiazem preparations.
    Hendriks MG; Dogterom P; Ebels JT; Oosterhuis B; Geertsema LR; Hulot T; Bianchetti G; Jonkman JH
    Fundam Clin Pharmacol; 1998; 12(5):559-65. PubMed ID: 9794155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers.
    Dimmitt DC; Bhargava VO; Arumugham T; Eller M; Weir SJ
    Am J Ther; 1998 May; 5(3):173-9. PubMed ID: 10099056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers.
    Lippert CL; Arumugham T; Bhargava VO; Eller M; Weir SJ
    Biopharm Drug Dispos; 1996 Jan; 17(1):43-53. PubMed ID: 8991490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.
    Leeuwenkamp OR; Visscher HW; Mensink CK; Jonkman JH
    Eur J Clin Pharmacol; 1994; 46(3):243-7. PubMed ID: 8070505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
    Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
    Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers.
    Robbins-Weilert DK; Giesing DH; Weir SJ
    Am J Ther; 1999 Jul; 6(4):211-6. PubMed ID: 11329099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of diltiazem bioavailability from 3 marketed extended-release products for once-daily administration: implications of chronopharmacokinetics and dynamics.
    Eradiri O; Midha KK
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):369-73. PubMed ID: 9314089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
    Scheiwe MW; Lankhaar G; Kleinbloesem CH
    Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability of diltiazem in prolonged-release oral preparations.
    Quiroga PA; Yuln GV; Palummo M; Cingolani A; Dall LL; Volonté MG
    Drug Dev Ind Pharm; 2001 Nov; 27(10):1099-106. PubMed ID: 11794812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects.
    Ziemniak J; Colligon I; Heald D
    Clin Ther; 1992; 14(2):158-65. PubMed ID: 1611640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetic profiles of amlodipine and of a sustained release form of diltiazem.
    Fourtillan JB; Ingrand I; Decourt JP; Istin B; Girault J
    Therapie; 1998; 53(2):121-6. PubMed ID: 9773111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo performance of controlled release pellets of diltiazem HCl.
    Nisarur-ur-Rahman ; K H Y; Jia Woei W
    Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination.
    Weir SJ; Dimmitt DC; Lanman RC; Morrill MB; Geising DH
    Biopharm Drug Dispos; 1998 Sep; 19(6):365-71. PubMed ID: 9737817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers.
    Shum L; Pieniaszek HJ; Robinson CA; Davidson AF; Widner PJ; Benedek IH; Flamenbaum W
    J Clin Pharmacol; 1996 Dec; 36(12):1161-8. PubMed ID: 9013374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
    Avramoff A; Domb AJ
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender related pharmacokinetics of diltiazem in healthy subjects.
    Sáenz-Campos D; Bayés MC; Martin S; Barbanoj MJ; Jané F
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):397-400. PubMed ID: 7582396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new extended-release formulation of diltiazem HCl for the treatment of mild-to-moderate hypertension.
    Frishman WH
    J Clin Pharmacol; 1993 Jul; 33(7):612-22. PubMed ID: 8366186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration.
    Sista S; Lai JC; Eradiri O; Albert KS
    J Clin Pharmacol; 2003 Oct; 43(10):1149-57. PubMed ID: 14517197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of grape juice and orange juice on the pharmacokinetics and pharmacodynamics of diltiazem in healthy human male subjects.
    Ahmed T; Sajid M; Singh T; Saini GS; Monif T; Saha N; Pillai KK
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):511-8. PubMed ID: 18826865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.